V 24343Alternative Names: V24343
Latest Information Update: 02 Aug 2011
At a glance
- Originator Vernalis
- Class Obesity therapies
- Mechanism of Action Cannabinoid receptor CB1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 17 Sep 2007 Preliminary results from a phase I clinical trial in overweight and obese volunteers added to the adverse events and Obesity therapeutic trials sections
- 17 Sep 2007 Vernalis completes a phase I trial in obesity in united Kingdom
- 11 Dec 2006 Phase-I clinical trials in Obesity in United Kingdom (unspecified route)